Clinical Trial

Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated October 14, 2025 (before its estimated April 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase 1b/2a study in allogenic hematopoietic stem cell transplant patients to investigate the safety, PK, PD and preliminary efficacy of multiple oral administrations of SNIPR001 when given concomitantly with SoC levofloxacin.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-21; most recent amendment 2025-10-09.
Trial Details
NCT Number NCT06938867
Lead Sponsor SNIPR Biome Aps.
Collaborators: Bill and Melinda Gates Foundation, Department of Health and Social Care, UK, Biomedical Advanced Research and Development Authority, Wellcome Trust, German Federal Ministry of Education and Research
Conditions E Coli Infections, Allogenic Transplant Patients
Enrollment 24 participants
Start Date 2025-02-25
Primary Completion 2026-04-01 (estimated)
Study Completion 2026-04-01 (estimated)
Updated on ClinicalTrials.gov 2025-10-14